Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic
Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic
With a vaccine for COVID-19 still a long way from being realized, Johns Hopkins immunologist Arturo Casadevall is working to revive a century-old blood-derived treatment for use in the United States in hopes of slowing the spread of the disease.
With the right pieces in place, the treatment could be set up at Johns Hopkins University in Baltimore within a matter of weeks, Casadevall says.
The technique uses antibodies from the blood plasma or serum of people who have recovered from COVID-19 infection to boost the immunity of newly infected patients and those at risk of contracting the disease. These antibodies contained in the blood’s serum have the ability to bind to and neutralize SARS-CoV-2, the virus that causes COVID-19. Casadevall—a Bloomberg Distinguished Professor of molecular microbiology and immunology and infectious diseases at the Johns Hopkins Bloomberg School of Public Health and School of Medicine—published a paper on the proposal today in The Journal of Clinical Investigation.
“Deployment of this option requires no research or development,” he says. “It could be deployed within a couple of weeks since it relies on standard blood-banking practices.”
“DEPLOYMENT OF THIS OPTION REQUIRES NO RESEARCH OR DEVELOPMENT. IT COULD BE DEPLOYED WITHIN A COUPLE OF WEEKS SINCE IT RELIES ON STANDARD BLOOD-BANKING PRACTICES.”
Arturo Casadevall
The medical concept—known as “convalescent plasma” or “convalescent sera”—dates back to the early 20th century, and was used successfully in the past to counter epidemics including mumps and the measles. In a recent Wall Street Journal op-ed, Casadevall points to a notable case preventing a measles outbreak at a U.S. prep school in 1934.
Experts say a challenge of the technique is that precise timing is important in order to maximize the boost to a patient’s immunity. The treatment is not envisioned as a panacea to treating coronavirus, but a temporary measure that could help until stronger options such as vaccines are available.
“It’s all doable—but to get it done it requires effort organization, resources… and people who have recovered from the disease who can donate the blood,” Casadevall says. He adds that many people have stepped up to the plate at Hopkins and are already working to put this system in place.
Casadevall says he believes the solution “could do a lot locally” in the Baltimore region. He also noted that Johns Hopkins could become the Investigational New Drug (IND) center in the U.S. for this treatment, helping to administer it across states.
Learning more about how to use the sera most effectively will require further clinical studies. “We will learn new science from this calamity,” Casadevall says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Covid-19 treatment
- Study: HIV cases along border spiked during COVID-19 pandemic
SAN DIEGO ( Border Report) — Researchers at UC San Diego and UC Irvine found that when border restrictions were in place during the COVID-19 pandemic, HIV transmissions in Tijuana and San Diego went ...
- Chinese scientist who first shared Covid-19 genome data sparks sympathy after lab closure battle
Zhang Yongzhen, who camped outside his Shanghai lab after parent hospital shut him out, has provoked wave of public sympathy and questioning of treatment meted out to noted virologist.
- Study finds metformin reduces COVID-19 viral load, viral rebound
A team of University of Minnesota researchers found that metformin, a drug commonly used to treat diabetes, can decrease the amount of COVID-19 virus in the body and lower the chances of the virus ...
- WHO recommends two new drugs for Covid-19 treatment
Baricitinib is an oral drug, used in the treatment of rheumatoid arthritis ... for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes older ...
- A better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to Paxlovid
A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in immunocompromised patients, according to Karen S. Anderson, Ph.D., professor of ...
Go deeper with Google Headlines on:
Covid-19 treatment
[google_news title=”” keyword=”covid-19 treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Covid-19
- Veterans injured by COVID-19 vaccine mandate could be paid under new bill
Warren Davidson is introducing a bill to make veterans eligible for disability compensation if they experienced side effects from the COVID-19 vaccine.
- This Chinese virologist shared crucial Covid-19 data. Then his research hit hurdles
Scientist was lauded for his 2020 disclosure, but in the years since, people who know him say he has faced unprecedented roadblocks in his career in China.
Go deeper with Google Headlines on:
Covid-19
[google_news title=”” keyword=”covid-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]